tirzepatide news november 2025 In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Arti Thangudu MD|Endocrinologist (Diabetes/Thyroid/Weight Loss)

Many patients remain asymptomatic until advanced disease develops, making incidental diagnosis through imaging or elevated liver enzymes common during routine health assessments

The initiative aims to bring affordable, transparent pricing to high-impact medications

Mild side effects may recur temporarily with each dose increase, but they are usually less severe and shorter-lasting than the initial response

E., Hans, D., Gonzalez Rodriguez, E., Vollenweider, P., Waeber, G., Marques-Vidal, P., & Lamy, O

& Iii, D

Microdosing GLP-1 Medications in Charleston GLP-1 medications such as semaglutide and tirzepatide have skyrocketed in popularity in a relatively short time and are reshaping the treatment of obesity and metabolic disease